Pharmaxis (Pharmaxis) Ending Cash Position : $3.81 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Ending Cash Position?

Pharmaxis's Ending Cash Position for the quarter that ended in Dec. 2023 was $3.81 Mil.

Pharmaxis's quarterly Ending Cash Position declined from Dec. 2022 ($11.10 Mil) to Jun. 2023 ($6.20 Mil) and declined from Jun. 2023 ($6.20 Mil) to Dec. 2023 ($3.81 Mil).

Pharmaxis's annual Ending Cash Position declined from Jun. 2021 ($14.31 Mil) to Jun. 2022 ($6.28 Mil) and declined from Jun. 2022 ($6.28 Mil) to Jun. 2023 ($6.20 Mil).

Pharmaxis Ending Cash Position Historical Data

The historical data trend for Pharmaxis's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis Ending Cash Position Chart

Pharmaxis Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Ending Cash Position

Get a 7-Day Free Trial

21.61

10.19

14.31

6.28

6.20

Pharmaxis Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															14.93	6.28	11.10	6.20	3.81

Pharmaxis Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pharmaxis's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	5.998	+	0.197
	=	6.20

Pharmaxis's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	6.177	+	-2.366
	=	3.81

Pharmaxis Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaxis (Pharmaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

UUDA:Germany SNT:Australia

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines

From GuruFocus

Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

By PRNewswire PRNewswire • 10-05-2021

FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis

By Business Wire Business Wire • 11-02-2020

Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

By PRNewswire PRNewswire • 08-04-2021

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

By PRNewswire PRNewswire • 11-09-2021

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

By PRNewswire PRNewswire • 08-31-2021

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

By PRNewswire PRNewswire • 08-05-2021